This company has shut down. Vector BioPharma is no longer operating — its last tracked round was a Series A in 2022.
Explore the Startup GraveyardVector BioPharma's cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics.
Vector BioPharma has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in August 2022.
Vector BioPharma's investors include Versant Ventures.
Vector BioPharma is headquartered in Basel, Switzerland.
Vector BioPharma's cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics.
Vector BioPharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vector BioPharma — Funding & Investors." VCBacked, August 10, 2022, https://www.vcbacked.co/company/vector-biopharma. Accessed August 14, 2026.
VCBacked. (2022). Vector BioPharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vector-biopharma
{{cite web |title=Vector BioPharma — Funding & Investors |url=https://www.vcbacked.co/company/vector-biopharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated